SEOUL-SEMICONDUCTOR
16.5.2019 15:02:10 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by scientists at the University of Basel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005262/en/
Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight. The two companies have since promoted this natural sunlight spectrum technology through its favorable effects on human well-being and sleep as a key value in the evolution of lighting.
There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” published in the Journal of Lighting and Research Technology published on March 24, 2019.
It is well established that light is one of the strongest control factors for human circadian rhythms, such as the secretion of the sleep promoting hormone melatonin. Thus, optimal lighting condition during daytime are crucial to prevent circadian rhythm disturbances which can lead to sleep disorders and other life-style related diseases. Over the past ten years, there have been related scientific studies in the fields of sleep, chronobiology, physiology, as well as the impact of light quality in elderly care.
According to Prof. Cajochen’s research, LED light sources with the same measured correlated color temperature (CCT) and intensity, but different spectral output, can have different effects on human behavior and physiology. LED light sources with a spectrum close to natural sunlight produced better visual comfort, more alertness, and happier moods in the morning and evening among the test participants, compared to those exposed to conventional spectrum LEDs. The research tested subjects’ visual comfort, circadian physiology, daytime alertness, mood, cognitive performance, and sleep after being exposed to both conventional LED light, and natural spectrum LED light for 49 hours in a laboratory setting.
Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers. Delta EEG activity (0.75–4.5Hz) was significantly higher after daylight-LED than conventional-LED exposure during the post-light exposure night.” [NOTE: Delta EEG (electroencephalogram) measurements record delta waves, the brain waves associated with Stage 3 non-rapid eye movement (NREM) sleep, or “slow-wave sleep” (SWS), and aid in characterizing the depth of sleep.]
By providing the same spectrum as sunlight and in the visible light range, SunLike Series natural spectrum LEDs deliver benefits to human well-being, consistent with the mechanisms of vision that impact both image forming and non-image forming aspects of the eye, as well as the control of circadian rhythms. While the qualities of artificial light have been described primarily with color and intensity thus far, SunLike Series natural spectrum LEDs have introduced light spectrum as another important factor in determining overall light quality.
“This research conducted by the University of Basel suggests another important aspect to the evolving direction of artificial light over the past eighty years. In addition to the properties of energy efficiency and long life, we have added the factor of ‘human well-being’ to modern LED light sources,” said Nam Ki-bum, sales executive vice-president of Seoul Semiconductor. “As the world’s first mass-produced LED devices to achieve natural sunlight quality, SunLike Series LEDs are advancing lighting technology in this important area as we continue to respond to market needs from our customers’ lighting applications.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005262/en/
Contact:
Seoul Semiconductor Inc. North America Andrew Smith Tel: +1 (901) 831-6614 Email: andrew.smith@seoulsemicon.com
Asia and Europe Jeong-hee Kim Tel: +82-70-4391-8311 Email: jeonghee.kim@seoulsemicon.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
